Multi-omics integration reveals molecular networks and regulators of psoriasis.

BackgroundPsoriasis is a complex multi-factorial disease, involving both genetic susceptibilities and environmental triggers. Genome-wide association studies (GWAS) and epigenome-wide association studies (EWAS) have been carried out to identify genetic and epigenetic variants that are associated with psoriasis. However, these loci cannot fully explain the disease pathogenesis.MethodsTo achieve a comprehensive mechanistic understanding of psoriasis, we conducted a systems biology study, integrating multi-omics datasets including GWAS, EWAS, tissue-specific transcriptome, expression quantitative trait loci (eQTLs), gene networks, and biological pathways to identify the key genes, processes, and networks that are genetically and epigenetically associated with psoriasis risk.ResultsThis integrative genomics study identified both well-characterized (e.g., the IL17 pathway in both GWAS and EWAS) and novel biological processes (e.g., the branched chain amino acid catabolism process in GWAS and the platelet and coagulation pathway in EWAS) involved in psoriasis. Finally, by utilizing tissue-specific gene regulatory networks, we unraveled the interactions among the psoriasis-associated genes and pathways in a tissue-specific manner and detected potential key regulatory genes in the psoriasis networks.ConclusionsThe integration and convergence of multi-omics signals provide deeper and comprehensive insights into the biological mechanisms associated with psoriasis susceptibility

Mitmekesiste bioloogiliste andmete ühendamine ja analüüs

Väitekirja elektrooniline versioon ei sisalda publikatsiooneTänu tehnoloogiate arengule on bioloogiliste andmete maht viimastel aastatel mitmekordistunud. Need andmed katavad erinevaid bioloogia valdkondi. Piirdudes vaid ühe andmestikuga saab bioloogilisi protsesse või haigusi uurida vaid ühest aspektist korraga. Seetõttu on tekkinud üha suurem vajadus masinõppe meetodite järele, mis aitavad kombineerida eri valdkondade andmeid, et uurida bioloogilisi protsesse tervikuna. Lisaks on nõudlus usaldusväärsete haigusspetsiifiliste andmestike kogude järele, mis võimaldaks vastavaid analüüse efektiivsemalt läbi viia. Käesolev väitekiri kirjeldab, kuidas rakendada masinõppel põhinevaid integratsiooni meetodeid erinevate bioloogiliste küsimuste uurimiseks. Me näitame kuidas integreeritud andmetel põhinev analüüs võimaldab paremini aru saada bioloogilistes protsessidest kolmes valdkonnas: Alzheimeri tõbi, toksikoloogia ja immunoloogia. Alzheimeri tõbi on vanusega seotud neurodegeneratiivne haigus millel puudub efektiivne ravi. Väitekirjas näitame, kuidas integreerida erinevaid Alzheimeri tõve spetsiifilisi andmestikke, et moodustada heterogeenne graafil põhinev Alzheimeri spetsiifiline andmestik HENA. Seejärel demonstreerime süvaõppe meetodi, graafi konvolutsioonilise tehisnärvivõrgu, rakendamist HENA-le, et leida potentsiaalseid haigusega seotuid geene. Teiseks uurisime kroonilist immuunpõletikulist haigust psoriaasi. Selleks kombineerisime patsientide verest ja nahast pärinevad laboratoorsed mõõtmised kliinilise infoga ning integreerisime vastavad analüüside tulemused tuginedes valdkonnaspetsiifilistel teadmistel. Töö viimane osa keskendub toksilisuse testimise strateegiate edasiarendusele. Toksilisuse testimine on protsess, mille käigus hinnatakse, kas uuritavatel kemikaalidel esineb organismile kahjulikke toimeid. See on vajalik näiteks ravimite ohutuse hindamisel. Töös me tuvastasime sarnase toimemehhanismiga toksiliste ühendite rühmad. Lisaks arendasime klassifikatsiooni mudeli, mis võimaldab hinnata uute ühendite toksilisust.A fast advance in biotechnological innovation and decreasing production costs led to explosion of experimental data being produced in laboratories around the world. Individual experiments allow to understand biological processes, e.g. diseases, from different angles. However, in order to get a systematic view on disease it is necessary to combine these heterogeneous data. The large amounts of diverse data requires building machine learning models that can help, e.g. to identify which genes are related to disease. Additionally, there is a need to compose reliable integrated data sets that researchers could effectively work with. In this thesis we demonstrate how to combine and analyze different types of biological data in the example of three biological domains: Alzheimer’s disease, immunology, and toxicology. More specifically, we combine data sets related to Alzheimer’s disease into a novel heterogeneous network-based data set for Alzheimer’s disease (HENA). We then apply graph convolutional networks, state-of-the-art deep learning methods, to node classification task in HENA to find genes that are potentially associated with the disease. Combining patient’s data related to immune disease helps to uncover its pathological mechanisms and to find better treatments in the future. We analyse laboratory data from patients’ skin and blood samples by combining them with clinical information. Subsequently, we bring together the results of individual analyses using available domain knowledge to form a more systematic view on the disease pathogenesis. Toxicity testing is the process of defining harmful effects of the substances for the living organisms. One of its applications is safety assessment of drugs or other chemicals for a human organism. In this work we identify groups of toxicants that have similar mechanism of actions. Additionally, we develop a classification model that allows to assess toxic actions of unknown compounds.https://www.ester.ee/record=b523255

An Ensemble of the iCluster Method to Analyze Longitudinal lncRNA Expression Data for Psoriasis Patients

BACKGROUND: Psoriasis is an immune-mediated, inflammatory disorder of the skin with chronic inflammation and hyper-proliferation of the epidermis. Since psoriasis has genetic components and the diseased tissue of psoriasis is very easily accessible, it is natural to use high-throughput technologies to characterize psoriasis and thus seek targeted therapies. Transcriptional profiles change correspondingly after an intervention. Unlike cross-sectional gene expression data, longitudinal gene expression data can capture the dynamic changes and thus facilitate causal inference. METHODS: Using the iCluster method as a building block, an ensemble method was proposed and applied to a longitudinal gene expression dataset for psoriasis, with the objective of identifying key lncRNAs that can discriminate the responders from the non-responders to two immune treatments of psoriasis. RESULTS: Using support vector machine models, the leave-one-out predictive accuracy of the 20-lncRNA signature identified by this ensemble was estimated as 80%, which outperforms several competing methods. Furthermore, pathway enrichment analysis was performed on the target mRNAs of the identified lncRNAs. Of the enriched GO terms or KEGG pathways, proteasome, and protein deubiquitination is included. The ubiquitination-proteasome system is regarded as a key player in psoriasis, and a proteasome inhibitor to target ubiquitination pathway holds promises for treating psoriasis. CONCLUSIONS: An integrative method such as iCluster for multiple data integration can be adopted directly to analyze longitudinal gene expression data, which offers more promising options for longitudinal big data analysis. A comprehensive evaluation and validation of the resulting 20-lncRNA signature is highly desirable

Omics and multi-omics analysis for the early identification and improved outcome of patients with psoriatic arthritis

The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients

A roadmap for the Human Developmental Cell Atlas

The Human Developmental Cell Atlas (HDCA) initiative, which is part of the Human Cell Atlas, aims to create a comprehensive reference map of cells during development. This will be critical to understanding normal organogenesis, the effect of mutations, environmental factors and infectious agents on human development, congenital and childhood disorders, and the cellular basis of ageing, cancer and regenerative medicine. Here we outline the HDCA initiative and the challenges of mapping and modelling human development using state-of-the-art technologies to create a reference atlas across gestation. Similar to the Human Genome Project, the HDCA will integrate the output from a growing community of scientists who are mapping human development into a unified atlas. We describe the early milestones that have been achieved and the use of human stem-cell-derived cultures, organoids and animal models to inform the HDCA, especially for prenatal tissues that are hard to acquire. Finally, we provide a roadmap towards a complete atlas of human development

Reframing Sepsis Immunobiology for Translation

Sepsis is a common and deadly condition. The current framing of dysregulated host immune responses within the sepsis immunobiology model into pro-inflammatory and immunosuppressive responses for testing novel treatments, have not resulted in successful immunomodulatory therapies. Thus, the recent focus has been to parse observable heterogeneity into subtypes of sepsis to enable personalized immunomodulation. In this perspective we highlight that many fundamental immunological concepts such as resistance, disease tolerance, resilience, resolution, and repair are not incorporated into the current sepsis immunobiology model. The focus for addressing heterogeneity in sepsis should broaden beyond subtyping, onto identifying deterministic molecularnetworks or dominant mechanisms. We explicitly reframe the dysregulated host immune responses in sepsis as pathologic disruption and/or alteration in homeostasis of the immune-driven resistance, tolerance and resolution mechanisms occurring concurrently. Our reframing highlights novel treatment opportunities and could enable successful immunomodulation in the future.Keywords: Sepsis, immunobiology, precision medicine, molecular mechanisms, subtyping, immunomodulation<br/